Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.

Read on WOBR AI →